Viamet Data for VT-1161 and VT-1598 to be Presented at The American Society for Microbiology’s ASM Microbe 2017 Conference

-- Presentations to include results of the highly successful Phase 2b study of VT-1161 in the treatment of recurrent vulvovaginal candidiasis (RVVC) and highlight the potent activity of Viamet’s product candidates against a breadth of endemic and multi-drug resistant fungal species --

RESEARCH TRIANGLE PARK, N.C.--()--Viamet Pharmaceuticals, Inc. today announced that data from its VT-1161 and VT-1598 therapeutic programs will be presented in multiple posters at The American Society for Microbiology’s ASM Microbe 2017 Conference, being held June 1-5 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The posters will include the first public presentation of Viamet’s successful Phase 2b results for VT-1161 in the treatment of recurrent vulvovaginal candidiasis (RVVC), and highlight the potent activity of Viamet’s antifungal candidates against a breadth of endemic and multi-drug resistant fungal species.

“Current antifungal therapies are limited by safety concerns, drug interactions and increasing reports of fungal resistance to treatment,” said Robert Schotzinger, M.D., Ph.D., President and CEO of Viamet. “Our objective in building Viamet’s extensive antifungal pipeline has been to design broad-spectrum agents that have the potential to provide superior efficacy and safety to meet the needs of patients and clinicians across a wide range of fungal diseases. Viamet’s poster presentations will showcase two of our advanced antifungal programs and include clinical data demonstrating the robust efficacy and safety of VT-1161 in the treatment of RVVC as well as preclinical data for VT-1598 demonstrating promising activity against drug-resistant and life-threatening fungal strains like Candida auris.”

Additional Details of the VT-1161 program presentations are as follows:

Title: Investigational Agent VT-1161 Has a Low In Vitro Potential for the Emergence of Stable Resistance in Candida spp.

Poster: 303
Date/Time: Sunday, June 4, 2017, 12:15 – 2:15 PM
Location: Exhibit Hall D, Exhibit and Poster Hall, Ernest N. Morial Convention Center
Session: 349 - AAID09 - Mycology: New Antifungal Agents II

Title: A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of VT-1161 in Healthy Japanese and Western Subjects

Poster: 310
Date/Time: Sunday, June 4, 2017, 12:30 – 2:30 PM
Location: Exhibit Hall D, Exhibit and Poster Hall, Ernest N. Morial Convention Center
Session: 349 - AAID09 - Mycology: New Antifungal Agents II

Title: Oral VT-1161 is Highly Effective and Safe in Patients with Recurrent Vulvovaginal Candidiasis- Results of REVIVE, a Multicenter Phase 2b Study

Poster: AAID LB21
Date/Time: Sunday, June 4, 2017, 12:30 – 2:30 PM
Location: Exhibit Hall D, Exhibit and Poster Hall, Ernest N. Morial Convention Center
Session: 334a - SUNDAY - AAID Late Breakers

Additional details of the VT-1598 program presentations are as follows:

Title: The Novel Fungal Cyp51 Inhibitor VT-1598 Demonstrates Potent In Vitro Activity Against Candida and Cryptococcus Species

Poster: 237
Date/Time: Saturday, June 3, 12:15 – 2:15 PM (Note: designated as an oral poster and will be presented at 1:15 PM.)
Oral Session: 240 – Design Evaluation and Novel Combinations Involving New Antimicrobials, 1:15 – 1:25 PM
Location: Exhibit Hall D, Exhibit and Poster Hall, Ernest N. Morial Convention Center
Session: 195 - AAID09 - Mycology: New Antifungal Agents I

Title: The Novel Fungal Cyp51 Inhibitor VT-1598 Demonstrates Potent In Vitro Activity Against Endemic Fungi, Aspergillus, and Rhizopus

Poster: 232
Date/Time: Saturday, June 3, 12:15 – 2:15 PM
Location: Exhibit Hall D, Exhibit and Poster Hall, Ernest N. Morial Convention Center
Session: 195 - AAID09 - Mycology: New Antifungal Agents I

Title: The Novel Fungal CYP51 Inhibitor VT-1598 Displays Fungicidal Activity In Vivo

Poster: 302
Date/Time: Sunday, June 4, 12:15 – 2:15 PM
Location: Exhibit Hall D, Exhibit and Poster Hall, Ernest N. Morial Convention Center
Session: 349 - AAID09 - Mycology: New Antifungal Agents II

Title: VT-1598 is Efficacious in a Murine Model of Respiratory Coccidioidomycosis

Poster: 305
Date/Time: Sunday, June 4, 12:15 – 2:15 PM
Location: Exhibit Hall D, Exhibit and Poster Hall, Ernest N. Morial Convention Center
Session: 349 - AAID09 - Mycology: New Antifungal Agents II

Title: In Vitro Activity of a Novel CYP51 Inhibitor, VT-1598, Against Clinical Isolates of Candida auris

Poster: 304
Date/Time: Sunday, June 4, 12:15 – 2:15 PM
Location: Exhibit Hall D, Exhibit and Poster Hall, Ernest N. Morial Convention Center
Session: 349 - AAID09 - Mycology: New Antifungal Agents II

About VT-1161
VT-1161 is a potent and selective, orally-administered inhibitor of fungal CYP51 which recently successfully completed Phase 2b clinical trials for the treatment of onychomycosis, or fungal nail infection, and recurrent vulvovaginal candidiasis (RVVC), a common and difficult to treat infection in women. VT-1161 blocks the production of ergosterol, an essential component of the fungal cell membrane. In preclinical studies, VT-1161 has demonstrated broad-spectrum activity against both dermatophytes and Candida species, including those species that cause onychomycosis and RVVC. Given the clinical and preclinical profile of VT-1161, Viamet believes that it may avoid the side effects that limit the use of current oral antifungal therapies, such as liver toxicity and drug-drug interactions. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to VT-1161 for the treatment of RVVC.

About VT-1598
VT-1598 is an orally available inhibitor of fungal CYP51 that has demonstrated high potency against a broad range of fungal pathogens, including common molds and yeasts. VT-1598 is also potent against a fungal class referred to as endemic fungi, which includes Coccidioides, Histoplasma and Blastomyces species. VT-1598 blocks the production of ergosterol, an essential component of the fungal cell membrane. Viamet is developing VT-1598 for the treatment of serious and life-threatening invasive fungal infections. Given the preclinical profile of VT-1598, Viamet believes that it may avoid the side effects that limit the use of current oral antifungal therapies, such as liver toxicity and drug-drug interactions. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and orphan drug designation to VT-1598 for the treatment of Valley Fever.

About Viamet (www.viamet.com)
Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior efficacy and safety profiles compared to currently marketed drugs.

This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet’s business, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc., VPS-3, Inc. and Viamet Pharmaceuticals (Bermuda), Ltd. The Viamet group of companies are based in the Research Triangle Park region of North Carolina, USA and Hamilton, Bermuda.

Contacts

MacDougall Biomedical Communications
Stefanie Tuck, +1-781-235-3060
stuck@macbiocom.com

Release Summary

Viamet to present data for two antifungal therapies at ASM Microbe 2017. This is the first public presentation of Viamet’s successful Phase 2b results for VT-1161 in the treatment of RVVC.

Contacts

MacDougall Biomedical Communications
Stefanie Tuck, +1-781-235-3060
stuck@macbiocom.com